TOP2A and EZH2 provide early detection of an aggressive prostate cancer subgroup

PURPOSE: Current clinical parameters do not stratify indolent from aggressive prostate cancer (PCa). Aggressive PCa, defined by the progression from localized disease to metastasis, is responsible for the majority of PCa-associated mortality. Recent gene expression profiling has proven successful in...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Clin Cancer Res
Egile Nagusiak: Labbé, David P., Sweeney, Christopher J., Brown, Myles, Galbo, Phillip, Rosario, Spencer, Wadosky, Kristine M., Ku, Sheng-Yu, Sjöström, Martin, Alshalalfa, Mohammed, Erho, Nicholas, Davicioni, Elai, Karnes, R. Jeffrey, Schaeffer, Edward M., Jenkins, Robert B., Den, Robert B., Ross, Ashley E., Bowden, Michaela, Huang, Ying, Gray, Kathryn P., Feng, Felix Y., Spratt, Daniel E., Goodrich, David W., Eng, Kevin H., Ellis, Leigh
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2017
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5690819/
https://ncbi.nlm.nih.gov/pubmed/28899973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-0413
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak